Cash Flow Statement

Amortization Amortization Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Deferred Charges Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Pension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

ADC Therapeutics (ADCT) Shares Issued (2020 - 2026)

ADC Therapeutics has reported Shares Issued over the past 6 years, most recently at $205000.0 for Q1 2026.

Quarterly results put Shares Issued at $205000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was -$42.0 million (down 44124.21% YoY), and the annual figure for FY2025 was $271000.0, up 18.86%.
Shares Issued reached $205000.0 in Q1 2026 per ADCT's latest filing, up from -$42.5 million in the prior quarter.
Across five years, Shares Issued topped out at $36.9 million in Q3 2024 and bottomed at -$42.5 million in Q4 2025.
Median Shares Issued over the past 4 years was $238000.0 (2025), compared with a mean of -$4.5 million.
The largest annual shift saw Shares Issued skyrocketed 2339594.66% in 2022 before it dropped 15.78% in 2025.
Over 4 years, Shares Issued stood at $6.1 million in 2022, then tumbled by 698.65% to -$36.7 million in 2024, then dropped by 15.78% to -$42.5 million in 2025, then skyrocketed by 100.48% to $205000.0 in 2026.
Business Quant data shows Shares Issued for ADCT at $205000.0 in Q1 2026, -$42.5 million in Q4 2025, and $271000.0 in Q2 2025.